Robert Herman Shmerling, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Infectious | 9 | 2021 | 345 | 1.500 |
Why?
|
| Antibodies, Antinuclear | 6 | 2022 | 344 | 1.420 |
Why?
|
| Gout | 8 | 2022 | 618 | 1.330 |
Why?
|
| Arthritis, Rheumatoid | 14 | 2017 | 3753 | 1.110 |
Why?
|
| Antirheumatic Agents | 8 | 2017 | 1368 | 0.860 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2022 | 2159 | 0.850 |
Why?
|
| Peptides, Cyclic | 3 | 2014 | 392 | 0.750 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2019 | 785 | 0.730 |
Why?
|
| Gout Suppressants | 4 | 2018 | 177 | 0.650 |
Why?
|
| Chondrocalcinosis | 2 | 2018 | 82 | 0.620 |
Why?
|
| Prosthesis-Related Infections | 2 | 2021 | 486 | 0.620 |
Why?
|
| Rheumatoid Factor | 7 | 2014 | 185 | 0.590 |
Why?
|
| Arthritis | 4 | 2018 | 666 | 0.580 |
Why?
|
| False Positive Reactions | 1 | 2019 | 956 | 0.550 |
Why?
|
| Curettage | 1 | 2016 | 73 | 0.530 |
Why?
|
| Synovial Fluid | 5 | 2021 | 395 | 0.490 |
Why?
|
| Fibromyalgia | 3 | 2010 | 401 | 0.490 |
Why?
|
| Rheumatology | 4 | 2017 | 611 | 0.480 |
Why?
|
| Independent Living | 5 | 2019 | 567 | 0.440 |
Why?
|
| Debridement | 1 | 2016 | 492 | 0.430 |
Why?
|
| Arthritis, Gouty | 1 | 2012 | 28 | 0.420 |
Why?
|
| Rheumatic Diseases | 5 | 2005 | 639 | 0.410 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2013 | 357 | 0.400 |
Why?
|
| Common Cold | 1 | 2011 | 63 | 0.370 |
Why?
|
| Laboratories | 1 | 2014 | 460 | 0.370 |
Why?
|
| Critical Pathways | 1 | 2014 | 473 | 0.370 |
Why?
|
| Eructation | 1 | 2010 | 6 | 0.360 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2021 | 1404 | 0.350 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 1369 | 0.350 |
Why?
|
| Giant Cell Arteritis | 2 | 2006 | 297 | 0.350 |
Why?
|
| Blood Sedimentation | 4 | 2014 | 234 | 0.340 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 2244 | 0.340 |
Why?
|
| Hyperpigmentation | 1 | 2011 | 117 | 0.340 |
Why?
|
| Osteoarthritis | 5 | 2011 | 1058 | 0.330 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 747 | 0.330 |
Why?
|
| Mucus | 1 | 2011 | 342 | 0.320 |
Why?
|
| Eyelids | 1 | 2011 | 277 | 0.320 |
Why?
|
| Xanthomatosis, Cerebrotendinous | 1 | 2008 | 9 | 0.320 |
Why?
|
| Nasal Mucosa | 1 | 2011 | 412 | 0.300 |
Why?
|
| Joints | 3 | 2016 | 321 | 0.300 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2002 | 288 | 0.290 |
Why?
|
| Cold Temperature | 1 | 2011 | 780 | 0.290 |
Why?
|
| Methotrexate | 2 | 2014 | 1718 | 0.280 |
Why?
|
| Glucocorticoids | 3 | 2015 | 2144 | 0.280 |
Why?
|
| Prednisone | 2 | 2018 | 1563 | 0.280 |
Why?
|
| Edema | 1 | 2011 | 769 | 0.280 |
Why?
|
| Tai Ji | 1 | 2010 | 287 | 0.280 |
Why?
|
| Eye Diseases | 1 | 2011 | 651 | 0.250 |
Why?
|
| Uric Acid | 4 | 2022 | 803 | 0.240 |
Why?
|
| Disability Evaluation | 3 | 2019 | 1825 | 0.240 |
Why?
|
| Evidence-Based Medicine | 3 | 2015 | 3670 | 0.230 |
Why?
|
| Autoantibodies | 2 | 2022 | 2116 | 0.230 |
Why?
|
| Complementary Therapies | 1 | 2008 | 486 | 0.220 |
Why?
|
| Pain Measurement | 7 | 2019 | 3523 | 0.210 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2004 | 215 | 0.210 |
Why?
|
| Postural Balance | 5 | 2015 | 617 | 0.210 |
Why?
|
| Humans | 76 | 2022 | 757566 | 0.210 |
Why?
|
| Glucosamine | 1 | 2002 | 128 | 0.210 |
Why?
|
| Chondroitin Sulfates | 1 | 2002 | 174 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 9163 | 0.200 |
Why?
|
| Transaminases | 1 | 2003 | 196 | 0.200 |
Why?
|
| Staphylococcal Infections | 3 | 2021 | 1406 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2011 | 3970 | 0.190 |
Why?
|
| Counseling | 1 | 2009 | 1540 | 0.190 |
Why?
|
| S-Adenosylmethionine | 1 | 2002 | 213 | 0.190 |
Why?
|
| Creatine Kinase | 1 | 2003 | 686 | 0.180 |
Why?
|
| Exercise Therapy | 1 | 2008 | 919 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 7982 | 0.180 |
Why?
|
| Immunologic Tests | 1 | 2021 | 103 | 0.180 |
Why?
|
| Breast Implants | 1 | 2003 | 410 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2006 | 3223 | 0.170 |
Why?
|
| Melanoma | 1 | 2018 | 5689 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 5798 | 0.150 |
Why?
|
| Vasculitis | 1 | 2002 | 522 | 0.150 |
Why?
|
| Mobility Limitation | 3 | 2019 | 400 | 0.150 |
Why?
|
| Osteomyelitis | 1 | 2021 | 407 | 0.150 |
Why?
|
| Cognition | 2 | 2014 | 6952 | 0.140 |
Why?
|
| Serologic Tests | 2 | 2014 | 384 | 0.140 |
Why?
|
| Pain | 4 | 2016 | 5063 | 0.140 |
Why?
|
| Bursitis | 1 | 2017 | 80 | 0.140 |
Why?
|
| Biological Products | 2 | 2015 | 903 | 0.130 |
Why?
|
| Retrospective Studies | 16 | 2021 | 79984 | 0.130 |
Why?
|
| Hypertension | 2 | 2020 | 8502 | 0.130 |
Why?
|
| Colchicine | 2 | 2018 | 257 | 0.130 |
Why?
|
| Anticholesteremic Agents | 1 | 2003 | 965 | 0.130 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 426 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 2940 | 0.130 |
Why?
|
| Fingers | 2 | 1988 | 506 | 0.130 |
Why?
|
| Musculoskeletal System | 2 | 2009 | 181 | 0.120 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 694 | 0.120 |
Why?
|
| Middle Aged | 28 | 2022 | 219192 | 0.120 |
Why?
|
| Pain Perception | 1 | 2016 | 196 | 0.120 |
Why?
|
| Endocarditis, Bacterial | 1 | 2019 | 442 | 0.120 |
Why?
|
| Male | 39 | 2022 | 358180 | 0.120 |
Why?
|
| Arthralgia | 3 | 2018 | 461 | 0.110 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 14637 | 0.110 |
Why?
|
| Aged | 33 | 2022 | 167890 | 0.110 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 58558 | 0.110 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 1402 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 7399 | 0.110 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 15207 | 0.100 |
Why?
|
| Geriatrics | 1 | 1996 | 387 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1263 | 0.100 |
Why?
|
| Qi | 1 | 2011 | 15 | 0.100 |
Why?
|
| Female | 37 | 2021 | 389943 | 0.100 |
Why?
|
| Toes | 1 | 2012 | 209 | 0.100 |
Why?
|
| Tendons | 1 | 2016 | 552 | 0.100 |
Why?
|
| Boston | 7 | 2019 | 9298 | 0.090 |
Why?
|
| Diagnosis, Differential | 7 | 2017 | 12951 | 0.090 |
Why?
|
| Reoperation | 1 | 2021 | 4279 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 2306 | 0.090 |
Why?
|
| Lactose Intolerance | 1 | 2010 | 28 | 0.090 |
Why?
|
| Indium | 1 | 1990 | 46 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 2018 | 0.090 |
Why?
|
| Control Groups | 1 | 2010 | 104 | 0.090 |
Why?
|
| Indium Radioisotopes | 1 | 1990 | 113 | 0.090 |
Why?
|
| Analgesics | 1 | 2017 | 1064 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 2267 | 0.080 |
Why?
|
| Hyperuricemia | 1 | 2012 | 224 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3591 | 0.080 |
Why?
|
| Activities of Daily Living | 3 | 2019 | 2414 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 3809 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 23816 | 0.080 |
Why?
|
| Disabled Persons | 2 | 2018 | 1224 | 0.080 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2008 | 34 | 0.080 |
Why?
|
| Hydrotherapy | 1 | 2008 | 6 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 1870 | 0.080 |
Why?
|
| Bacteria | 1 | 2019 | 2196 | 0.080 |
Why?
|
| Antilymphocyte Serum | 1 | 1989 | 482 | 0.070 |
Why?
|
| Cathartics | 1 | 2009 | 127 | 0.070 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 1583 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 15781 | 0.070 |
Why?
|
| Accidental Falls | 2 | 2018 | 1056 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 6292 | 0.070 |
Why?
|
| Orthotic Devices | 1 | 2008 | 129 | 0.070 |
Why?
|
| Sepsis | 2 | 2020 | 2579 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 809 | 0.070 |
Why?
|
| Leptin | 1 | 2015 | 1590 | 0.070 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 961 | 0.070 |
Why?
|
| Length of Stay | 1 | 2020 | 6384 | 0.070 |
Why?
|
| Joint Diseases | 1 | 1990 | 457 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2011 | 1955 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 39020 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 7366 | 0.060 |
Why?
|
| Seasons | 1 | 2011 | 1513 | 0.060 |
Why?
|
| Prevalence | 6 | 2019 | 15640 | 0.060 |
Why?
|
| Face | 1 | 2011 | 1017 | 0.060 |
Why?
|
| Risk Factors | 10 | 2020 | 73708 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1791 | 0.060 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2010 | 453 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2015 | 1234 | 0.060 |
Why?
|
| Physicians | 1 | 2022 | 4577 | 0.060 |
Why?
|
| Brain | 1 | 2011 | 26952 | 0.060 |
Why?
|
| Physical Therapy Modalities | 1 | 2008 | 536 | 0.060 |
Why?
|
| Medical Records | 2 | 2002 | 1406 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 375 | 0.060 |
Why?
|
| Abdomen | 1 | 2010 | 1126 | 0.060 |
Why?
|
| Body Weight | 1 | 2015 | 4602 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1177 | 0.060 |
Why?
|
| Resuscitation | 1 | 1988 | 661 | 0.060 |
Why?
|
| Acetaminophen | 2 | 2018 | 552 | 0.060 |
Why?
|
| Rhinitis | 1 | 2011 | 746 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2004 | 221 | 0.050 |
Why?
|
| Diet | 1 | 2021 | 8001 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 11082 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 1188 | 0.050 |
Why?
|
| Silicones | 1 | 2003 | 227 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 816 | 0.050 |
Why?
|
| Acupuncture | 1 | 2002 | 90 | 0.050 |
Why?
|
| Biopsy | 2 | 2006 | 6757 | 0.050 |
Why?
|
| Plants, Medicinal | 1 | 2002 | 164 | 0.050 |
Why?
|
| Adult | 12 | 2022 | 219725 | 0.050 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2011 | 1079 | 0.050 |
Why?
|
| Cohort Studies | 7 | 2018 | 41190 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 4845 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2003 | 415 | 0.050 |
Why?
|
| Obesity | 2 | 2015 | 12870 | 0.050 |
Why?
|
| Quality of Life | 3 | 2018 | 13263 | 0.050 |
Why?
|
| Hospitalization | 2 | 2020 | 10634 | 0.050 |
Why?
|
| Physical Examination | 2 | 2009 | 1245 | 0.050 |
Why?
|
| Chlorthalidone | 1 | 2020 | 21 | 0.040 |
Why?
|
| Lisinopril | 1 | 2020 | 55 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 604 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2007 | 831 | 0.040 |
Why?
|
| Amlodipine | 1 | 2020 | 84 | 0.040 |
Why?
|
| Atenolol | 1 | 2020 | 99 | 0.040 |
Why?
|
| Motor Activity | 1 | 2009 | 2685 | 0.040 |
Why?
|
| Attitude to Health | 1 | 1988 | 2024 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 11422 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 655 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 21217 | 0.040 |
Why?
|
| Safety | 1 | 2003 | 1147 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 2904 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 2003 | 551 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 64242 | 0.040 |
Why?
|
| Prognosis | 3 | 2017 | 29488 | 0.040 |
Why?
|
| Vitamin E | 1 | 2022 | 870 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2002 | 772 | 0.040 |
Why?
|
| Aging | 1 | 2016 | 8654 | 0.040 |
Why?
|
| Knee | 1 | 2019 | 276 | 0.040 |
Why?
|
| Olecranon Process | 1 | 2017 | 16 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2004 | 1332 | 0.040 |
Why?
|
| Dementia | 1 | 2011 | 2649 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2003 | 1190 | 0.030 |
Why?
|
| Israel | 1 | 2018 | 721 | 0.030 |
Why?
|
| Weight Loss | 1 | 2008 | 2672 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 1999 | 411 | 0.030 |
Why?
|
| United States | 5 | 2021 | 71902 | 0.030 |
Why?
|
| ROC Curve | 2 | 1996 | 3562 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2017 | 564 | 0.030 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 370 | 0.030 |
Why?
|
| Patella | 1 | 2017 | 313 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 1658 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 2048 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2015 | 3887 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3799 | 0.030 |
Why?
|
| Suburban Population | 1 | 2014 | 53 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 1988 | 3238 | 0.030 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 706 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 1995 | 252 | 0.030 |
Why?
|
| Teaching Rounds | 1 | 2018 | 275 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2017 | 305 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2018 | 489 | 0.030 |
Why?
|
| Vitamins | 1 | 2022 | 1632 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 4159 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2019 | 1088 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2019 | 760 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 1989 | 10167 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2847 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 1996 | 1155 | 0.020 |
Why?
|
| Comorbidity | 3 | 2011 | 10477 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 10135 | 0.020 |
Why?
|
| Age Factors | 2 | 2020 | 18326 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2022 | 12261 | 0.020 |
Why?
|
| Pelvic Bones | 1 | 1992 | 270 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2022 | 3387 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2009 | 26176 | 0.020 |
Why?
|
| Gait | 1 | 2014 | 814 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 1458 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1995 | 1890 | 0.020 |
Why?
|
| General Surgery | 1 | 2020 | 1674 | 0.020 |
Why?
|
| Spinal Stenosis | 1 | 2011 | 262 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 1628 | 0.020 |
Why?
|
| Pregnancy | 1 | 2009 | 29712 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7502 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2009 | 9624 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2011 | 747 | 0.020 |
Why?
|
| Young Adult | 3 | 2019 | 58755 | 0.020 |
Why?
|
| Critical Care | 1 | 2020 | 2690 | 0.020 |
Why?
|
| Critical Illness | 1 | 2020 | 2705 | 0.020 |
Why?
|
| Synovial Membrane | 1 | 1990 | 524 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2020 | 3428 | 0.020 |
Why?
|
| Echocardiography | 1 | 2019 | 4963 | 0.020 |
Why?
|
| Urban Population | 1 | 2014 | 2023 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2003 | 4652 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1990 | 1595 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 8426 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 1992 | 520 | 0.020 |
Why?
|
| Consensus | 1 | 2015 | 3097 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1990 | 1976 | 0.020 |
Why?
|
| Algorithms | 1 | 2006 | 13952 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2011 | 9263 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8512 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2011 | 709 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 6337 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2009 | 436 | 0.010 |
Why?
|
| Massachusetts | 1 | 2017 | 8815 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2020 | 8453 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 20037 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2009 | 2922 | 0.010 |
Why?
|
| Patient Selection | 1 | 2015 | 4235 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2017 | 3241 | 0.010 |
Why?
|
| Research Design | 1 | 1999 | 6152 | 0.010 |
Why?
|
| Disclosure | 1 | 1988 | 743 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1992 | 1865 | 0.010 |
Why?
|
| Walking | 1 | 2009 | 1190 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4760 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2007 | 640 | 0.010 |
Why?
|
| Informed Consent | 1 | 1988 | 1003 | 0.010 |
Why?
|
| Health Surveys | 1 | 2011 | 4056 | 0.010 |
Why?
|
| Radiography | 2 | 1992 | 6956 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2011 | 1908 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2009 | 1385 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 3762 | 0.010 |
Why?
|
| Decision Making | 2 | 1999 | 3909 | 0.010 |
Why?
|
| Knee Joint | 1 | 2009 | 1664 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2009 | 2058 | 0.010 |
Why?
|
| Depression | 1 | 2018 | 8049 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1996 | 22022 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2011 | 2781 | 0.010 |
Why?
|
| Professional Practice | 1 | 1999 | 313 | 0.010 |
Why?
|
| Information Systems | 1 | 1999 | 396 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2015 | 12868 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1999 | 782 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 4338 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1999 | 600 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 5815 | 0.010 |
Why?
|
| Osteosclerosis | 1 | 1992 | 42 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 25924 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1992 | 419 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1995 | 2610 | 0.000 |
Why?
|
| Antibodies | 1 | 1995 | 2420 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 3734 | 0.000 |
Why?
|
| Spinal Diseases | 1 | 1992 | 559 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1990 | 54092 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1995 | 3996 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1995 | 8550 | 0.000 |
Why?
|
| Adolescent | 1 | 1995 | 87819 | 0.000 |
Why?
|